drugset / Trial / NCT03847207
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
RandomizedSequentialDouble-blindTreatment
Summary
A Phase 1, first in human, three-part, single centre study to assess the safety, tolerability, PK and PD of single ascending subcutaneous doses of HTL0030310 in healthy subjects
Timeline
- Start
- 2019-01-23
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HTL0030310 | Unknown | — | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 600 ug | Subcutaneous |
Indications
No indication recorded.